Impact of evolocumab on periprocedural microvascular damage in patients undergoing percutaneous coronary intervention (PCI)
- Conditions
- stable coronary artery disease
- Registration Number
- JPRN-UMIN000031990
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Not provided
(1)Any prior use of PCSK9 inhibitor therapy. (2)Patients with previous MI in the terriory of the target coronary artery. (3)Patients with target vessels which are two, three, or LMT. (4)Patients with recent MI in past 6 weeks (5)Patients with heart failure of New York Heart Failure Association class III or IV (6)Patients with last known left ventricular ejection fraction <30%. (7)Patients with serious renal impairment with an eGFR <30 mL/min/1.73 m2 at screening (8)Patients with hepatic dysfunction with AST or ALT 3-fold of upper limit of normal (ULN) at screening (9)Patients who are pregnant, possibly pregnant, or breast feeding. (10)Patients who have been enrolled in other clinical studies at the same time with this study (excluding observational studies such as registry studies). (11)Patients who are judged by the investigator or subinvestigators to be not suitable for participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Index of microvascular resistance after PCI
- Secondary Outcome Measures
Name Time Method